Protagonist Therapeutics Announces Positive Topline Results

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Singapore , Dineshv Patel , Jami Taylor , World Congress , Protagonist Therapeutics Inc , Janssen Pharmaceutical Companies Of Johnson , Collaboration Agreement With Protagonist Therapeutics Inc , Janssen Biotech Inc , Exchange Commission , Johnson , Janssen Biotech For The Continued Development , Protagonist Therapeutics , Janssen Biotech , Janssen Pharmaceutical Companies , Psoriasis Area , Severity Index , For Protagonist , Global Assessment , Psoriasis Symptoms , Signs Diary , Dermatology Life Quality Index , Private Securities Litigation Reform Act , Risk Factor , Dose Ranging Study , Moderate To Severe Plaque Psoriasis , In Class Oral Peptide Systemically Targeting , Cell Penetration , Protagonist Reports Positive Results , Pre Clinical Studies , Janssen Enters Into Worldwide Exclusive License , For The Oral , Antagonist Drug Candidate For The Treatment , Inflammatory Bowel , Accessed June , Protagonist Therapeutics Announces Amendment , Continued Development ,